🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Julien Taı̈eb

Université Paris Cité

ORCID: 0000-0002-9955-4753

Also affiliated with Hôpital Européen Georges-Pompidou

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 4 papers. Top paper: “Evaluation of the change of outcomes over a 10-year period in patients with stage III colon cancer: pooled analysis of 6501 patients treated with fluorouracil, leucovorin, and oxaliplatin in the ACCENT database”.

Evaluation of the change of outcomes over a 10-year period in patients with stage III colon cancer: pooled analysis of 6501 patients treated with fluorouracil, leucovorin, and oxaliplatin in the ACCENT database

Annals of Oncology(2020)10.1016/j.annonc.2019.12.007

N/A

1.4DataRank · unranked

34 citations

Jun Yin, Richard M. Goldberg, Levi Pederson, Norman Wolmark, Steven R. Alberts +11 more

Overall survival (OS) and long-term disease-free survival (DFS) of three versus six months of adjuvant (adj) oxaliplatin and fluoropyrimidine-based therapy for patients (pts) with stage III colon cancer (CC): Final results from the IDEA (International Duration Evaluation of Adj chemotherapy) collaboration.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.4004

N/A

0DataRank · unranked

36 citations

Thierry André, Jeffrey A. Meyerhardt, Axel Grothey, Timothy Iveson, Takayuki Yoshino +15 more

Clinicopathological and molecular biological characteristics of early-onset stage II/III colorectal adenocarcinoma: An analysis of 25 studies with 47,184 patients (pts) in the adjuvant colon cancer end points (ACCENT) database.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.4099

N/A

0DataRank · unranked

1 citations

Jesse G. Dixon, Hiral D. Parekh, Steven R. Alberts, Greg Yothers, Carmen J. Allegra +15 more

Reevaluating Disease-Free Survival as an Endpoint vs Overall Survival in Stage III Adjuvant Colon Cancer Trials

JNCI Journal of the National Cancer Institute(2021)10.1093/jnci/djab187

N/A

0DataRank · unranked

16 citations

Mohamed E. Salem, Jesse G. Dixon, Zhaohui Jin, Romain Cohen, Aimery DeGramont +16 more